Literature DB >> 9790118

CD2-, CD4+, CD56+ agranular natural killer cell lymphoma of the skin.

N Uchiyama1, K Ito, K Kawai, F Sakamoto, M Takaki, M Ito.   

Abstract

We present a case of CD56-positive cutaneous lymphoma with a clinical appearance resembling angiosarcoma. The biopsy specimen showed angiocentric infiltrates of small to medium-sized cells positive for CD4, CD45, and CD56 but negative for CD2, surface and cytoplasmic CD3, CD8, CD20, and CD57. There was no detectable clonal rearrangement of either TCRbeta or TCRgamma genes and no dense core granules in the cytoplasm. Epstein-Barr virus was not detected. The patient died of an unrelated disease 20 months after initial biopsy, although there was some response to interleukin-2, radiotherapy, and VP-16. The results suggest that our case does not precisely match the recently proposed variants of CD56-positive lymphoma, namely nasal T/natural killer cell lymphoma and blastic natural killer cell lymphoma. Agranular natural killer cell lymphomas similar to our case in the immunophenotype have been reported to be indolent and occur in the skin. These lymphomas may be a distinct subtype and have a predilection for involving the skin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790118     DOI: 10.1097/00000372-199810000-00018

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  2 in total

1.  Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset.

Authors:  Haisheng Yu; Peng Zhang; Xiangyun Yin; Zhao Yin; Quanxing Shi; Ya Cui; Guanyuan Liu; Shouli Wang; Pier Paolo Piccaluga; Taijiao Jiang; Liguo Zhang
Journal:  Protein Cell       Date:  2015-03-18       Impact factor: 14.870

Review 2.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.